Peptide-Human Leukocyte Antigen (pHLA) complex (pHLA)

The Peptide-Human Leukocyte Antigen (pHLA) complex consists of a peptide fragment bound within the groove of an HLA molecule, displayed on the surface of host cells for surveillance by T-lymphocytes (Murphy & Weaver, 2016). This complex serves as the primary signal for the adaptive immune system, where the T-cell receptor (TCR) recognizes the specific combination of the HLA molecule and the presented peptide to initiate an immune response (StatPearls, 2023). In healthy states, pHLA complexes present self-peptides to maintain tolerance; however, in disease states, they may present viral, mutated, or overexpressed tumor antigens (PubMed, 2021). Allogeneic pHLA complexes, which differ between individuals, are the primary targets in transplant rejection and graft-versus-host disease (GvHD) (NIH, 2022). Modern immunotherapies, such as TCR-engineered T-cells (e.g., Afamitresgene autoleucel) and bispecific T-cell engagers (e.g., Tebentafusp), are designed to specifically target these complexes to eliminate malignant cells (FDA, 2022; FDA, 2024). Conversely, immunosuppressive strategies aim to dampen the recognition of these complexes in autoimmune and transplant settings to prevent tissue damage. The specificity of the pHLA-TCR interaction is critical, as cross-reactivity with similar self-peptides can lead to severe off-target toxicities. Overall, the pHLA complex is a central node in immunology, acting as both a trigger for natural immunity and a precise target for synthetic biology in medicine.

Other names

pMHCMHC-peptide complexHLA-peptide complexMajor Histocompatibility Complex-peptide complexAntigen-HLA complexp-HLA

Therapeutic agents target the pHLA complex either to redirect T-cell cytotoxicity against cells presenting specific antigens, such as tumor-associated peptides, or to inhibit the T-cell activation sequence triggered by pHLA recognition in autoimmune and transplant contexts (Murphy & Weaver, 2016; FDA, 2022).